Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout ...
FDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data from the IOB-013 clinical trial Company plans to design new registrational study for Cylembio for the ...
After launching a multi-campus phased rollout of the predictive insulin dosing software, Philadelphia-based Temple Health’s University Hospital has reduced hypoglycemia rates two- to threefold. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback